Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The Respiratory Syncytial Virus (RSV) G glycoprotein is a major surface protein of the RSV virion, functioning primarily as the viral attachment protein. It mediates the initial binding of RSV to host cells, targeting ciliated epithelial cells in the human respiratory tract. The ectodomain contains two heavily glycosylated mucin-like regions separated by a central conserved, unglycosylated cysteine-rich "noose" stabilized by disulfide bonds. There are hypervariable segments at the C-terminal region of the ectodomain, contributing to antigenic diversity among strains. In immortalized cell lines it binds heparan sulfate proteoglycans (HSPG) and in airway epithelium models it interacts with CX3CR1. Both F and G proteins elicit neutralizing antibody responses during natural infection. G remains an important antigenic target because it acts as a neutralizing antigen and contributes significantly to immune evasion through its variability and heavy glycosylation shield.
N/A
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Respiratory Syncytial Virus G Glycoprotein (G glycoprotein).